MLBON.PA Bonyf NV
- Market cap
- EUR 1.12M
- P/E
- -
- P/B
- 17.90x
- ROE
- -1.4%
- Dividend yield
- -
- Fundamental score
- 0.8/5
Ratios use the latest price and the fiscal year ending Dec 2024.
Is MLBON.PA undervalued?
Graham numberThe Graham number of Bonyf NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bonyf NV fundamental analysis
2 of 11 checks passedROE 0/2
Negative ROE (-22.44%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-5.39%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.
DER 1/2
The stock maintains a fair debt to equity ratio (96%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.
Assets Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Graham Number 0/1
The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Bonyf NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bonyf NV
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine dis…
Full company profileBonyf NV financial statements
Bonyf NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.20M | 2.37M | 277K | 309K | 281K |
| Gross Profit | 2.16M | 1.66M | 10.0K | 26.4K | 22.6K |
| Operating Income | 226K | -48.9K | -318K | -39.9K | -34.7K |
| EBITDA | 268K | 3.86K | -267K | -39.9K | -33.7K |
| Net Income | 191K | -70.2K | -3.32M | -1.04M | -36.5K |
| EPS | 0.32 | -0.12 | -5.64 | -1.77 | -0.06 |
| Balance Sheet | |||||
| Total Assets | 1.39M | 1.38M | 4.17M | 3.09M | 3.34M |
| Total Liabilities | 1.04M | 1.10M | 445K | 412K | 696K |
| Shareholders' Equity | 345K | 280K | 3.73M | 2.68M | 2.64M |
| Cash & Short-term Investments | 38.8K | 50.5K | 393.08 | 9.96K | 5.03K |
| Total Debt | 222K | 268K | - | 75.0K | 36.0K |
| Cash Flow | |||||
| Operating Cash Flow | - | 57.0M | - | - | - |
| Capital Expenditure | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | 57.0M | - | - | - |
| Ratios | |||||
| ROE | 55.2% | -25.1% | -89.1% | -39.0% | -1.4% |
| ROA | 13.7% | -5.1% | -79.6% | -33.8% | -1.1% |
| Net Profit Margin | 6.0% | -3.0% | -1,196.1% | -337.7% | -13.0% |
| Debt to Equity | 0.64x | 0.96x | - | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bonyf NV dividends
Bonyf NV has not paid dividends in the last 4 fiscal years.
Who owns Bonyf NV
Ownership data of Bonyf NV is not available yet.
Bonyf NV company profile
- Company name
- Bonyf NV
- Ticker
- MLBON.PA
- ISIN
- BE6333353298
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- Kalvekeetdijk 179, Knokke-Heist, Belgium, 8300
- Phone
- 32 0 506 09 906
- Website
- bonyf.com
About Bonyf NV
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine disinfecting denture tabs; Denture Repair-fix, an instant repair system for broken or cracked dentures and teeth detached from dentures; Fixobridge, a ready to use cement that fixes dislodged crowns, inlays, and bridges; denture relining cushion for ill-fitting dentures; Effervescent denture cleanser tablets; Superior denture adhesive creams; and Cavifix, a synthetic resin-based filling material to temporarily seal newly formed cavities and repair lost fillings or inlays. In addition, the company offers orthodontic care products, including NitrAdine Ortho & Junior disinfecting tabs to clean and disinfect removable orthodontic appliances; and wound care products comprising HeelFix and FingerFix paste dressing products for cracks and chapped skin on feet and hands. bonyf N.V. was incorporated in 1979 and is headquartered in Knokke-Heist, Belgium.
Bonyf NV management
6- Mr. Jean-Pierre BogaertFounder, CEO & Director
- Mr. Vait CerkeziChief Operating Officer
- Dr. Frank ZeunerChief Scientific Officer
- Mr. Chris BatjerHead of Quality & Compliance Management
- Mr. Djezmi CherkeziHead of Production
- Mr. Marc BogaertChief Product Officer